Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-005847
Filing Date
2025-04-29
Accepted
2025-04-29 16:15:30
Documents
77
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20250331x10q.htm   iXBRL 10-Q 1966267
2 EX-10.1 knsa-20250331xex10d1.htm EX-10.1 77160
3 EX-31.1 knsa-20250331xex31d1.htm EX-31.1 11243
4 EX-31.2 knsa-20250331xex31d2.htm EX-31.2 10399
5 EX-32.1 knsa-20250331xex32d1.htm EX-32.1 6206
6 EX-32.2 knsa-20250331xex32d2.htm EX-32.2 6180
  Complete submission text file 0001558370-25-005847.txt   8284757

Data Files

Seq Description Document Type Size
7 EX-101.SCH knsa-20250331.xsd EX-101.SCH 54036
8 EX-101.CAL knsa-20250331_cal.xml EX-101.CAL 52167
9 EX-101.DEF knsa-20250331_def.xml EX-101.DEF 290156
10 EX-101.LAB knsa-20250331_lab.xml EX-101.LAB 466424
11 EX-101.PRE knsa-20250331_pre.xml EX-101.PRE 399225
80 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20250331x10q_htm.xml XML 1339378
Mailing Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ
Business Address 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ 7814319100
Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 25887799
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)